{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:15:48Z","timestamp":1791476148869,"version":"4.3.4"},"reference-count":252,"publisher":"Bentham Science Publishers Ltd.","issue":"35","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,12,13]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>There is always a need for alternative and efficient methods of drug delivery. The\nnasal cavity can be considered as a non-invasive and efficient route of administration. It has\nbeen used for local, systemic, brain targeting, and vaccination delivery. Although many intranasal\nproducts are currently available on the market, the majority is used for local delivery\nwith fewer products available for the other targets. As nanotechnology utilization in drug delivery\nhas rapidly spread out, the nasal delivery has become attractive as a promising approach.\nNanoparticulate systems facilitate drug transportation across the mucosal barrier, protect\nthe drug from nasal enzyme degradation, enhance the delivery of vaccines to the lymphoid\ntissue of the nasal cavity with an adjuvant activity, and offer a way for peptide delivery\ninto the brain and the systemic circulation, in addition to their potential for brain tumor treatment.\nThis review article aims at discussing the potential benefit of the intranasal nanoparticulate\nsystems, including nanosuspensions, lipid and surfactant, and polymer-based nanoparticles\nas regards productive intranasal delivery. The aim of this review is to focus on the topicalities\nof nanotechnology applications for intranasal delivery of local, systemic, brain, and\nvaccination purposes during the last decade, referring to the factors affecting delivery, regulatory\naspects, and patient expectations. This review further identifies the benefits of applying\nthe Quality by Design approaches (QbD) in product development. According to the reported\nstudies on nanotechnology-based intranasal delivery, potential attention has been focused on\nbrain targeting and vaccine delivery with promising outcomes. Despite the significant research\neffort in this field, nanoparticle-based products for intranasal delivery are not available.\nThus, further efforts are required to promote the introduction of intranasal nanoparticulate\nproducts that can meet the requirements of regulatory affairs with high patient acceptance.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666190827151741","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T10:49:20Z","timestamp":1566902960000},"page":"6459-6492","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery"],"prefix":"10.2174","volume":"26","author":[{"given":"Areen","family":"Alshweiat","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ambrus","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IIdik\u00f3","family":"Cs\u00f3ka","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijpharm.2004.07.019","volume":"284","author":"Kipp J.E.","year":"2004","unstructured":"Kipp J.E.; The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004,284(1-2),109-122","journal-title":"Int J Pharm"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/0192623307310946","volume":"36","author":"Merisko-Liversidge E.M.","year":"2008","unstructured":"Merisko-Liversidge E.M.; Liversidge G.G.; Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008,36(1),43-48","journal-title":"Toxicol Pathol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","volume":"73","author":"Prabhakar U.","year":"2013","unstructured":"Prabhakar U.; Maeda H.; Jain R.K.; Sevick-Muraca E.M.; Zamboni W.; Farokhzad O.C.; Barry S.T.; Gabizon A.; Grodzinski P.; Blakey D.C.; Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013,73(8),2412-2417","journal-title":"Cancer Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1124\/dmd.112.044925","volume":"40","author":"Kadam R.S.","year":"2012","unstructured":"Kadam R.S.; Bourne D.W.A.; Kompella U.B.; Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos 2012,40(7),1380-1388","journal-title":"Drug Metab Dispos"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.nano.2005.03.002","volume":"1","author":"Kawasaki E.S.","year":"2005","unstructured":"Kawasaki E.S.; Player A.; Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 2005,1(2),101-109","journal-title":"Nanomedicine"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fphar.2017.00051","volume":"8","author":"Li B.","year":"2017","unstructured":"Li B.; Li Q.; Mo J.; Dai H.; Drug-loaded polymeric nanoparticles for cancer stem cell targeting. Front Pharmacol 2017,8,51","journal-title":"Front Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2217\/nnm.10.10","volume":"5","author":"Trivedi R.","year":"2010","unstructured":"Trivedi R.; Kompella U.B.; Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond) 2010,5(3),485-505","journal-title":"Nanomedicine (Lond)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","volume":"83","author":"Zhang L.","year":"2008","unstructured":"Zhang L.; Gu F.X.; Chan J.M.; Wang A.Z.; Langer R.S.; Farokhzad O.C.; Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008,83(5),761-769","journal-title":"Clin Pharmacol Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","volume":"69","author":"Gaumet M.","year":"2008","unstructured":"Gaumet M.; Vargas A.; Gurny R.; Delie F.; Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008,69(1),1-9","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/978-3-319-08084-0_15","author":"Gaspar R.S.","year":"2014","unstructured":"Gaspar R.S.; Florindo H.F.; Silva L.C.; Videira M.A.; Corvo M.L.; Martins B.F.; Silva-Lima B.; Regulatory Aspects\nof Oncologicals: Nanosystems Main Challenges. Nano-Oncologicals New Targeting and Delivery Approaches Alonso, M.; Garcia-Fuentes, M., Eds.; Springer: Cham2014,425-452","journal-title":"Nano-Oncologicals New Targeting and Delivery Approaches"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/138920010791110836","volume":"11","author":"Cai Z.","year":"2010","unstructured":"Cai Z.; Wang Y.; Zhu L-J.; Liu Z-Q.; Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab 2010,11(2),197-207","journal-title":"Curr Drug Metab"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1039\/c2cs15260f","volume":"41","author":"Doane T.L.","year":"2012","unstructured":"Doane T.L.; Burda C.; The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem Soc Rev 2012,41(7),2885-2911","journal-title":"Chem Soc Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijpharm.2006.01.008","volume":"312","author":"Kocbek P.","year":"2006","unstructured":"Kocbek P.; Baumgartner S.; Kristl J.; Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006,312(1-2),179-186","journal-title":"Int J Pharm"},{"key":"ref=14","unstructured":"Nanotechnology - FDA\u2019s Approach to Regulation of Nanotechnology Products. Available from ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.fda.gov\">www.fda.gov [Accessed: Jul 24,2017]"},{"key":"ref=15","unstructured":"European Medicines Agency - Human regulatory - Human\nmedicines: regulatory information. Available from:  https:\/\/www.ema.europa.eu\/en\/human-medicines-regulatory-information [Accessed: Jul 24,2017]"},{"key":"ref=16","year":"2002","unstructured":"Guidance for Industry Nasal Spray and Inhalation Solution Suspension and Spray Drug Products - Chemistry; Manufacturing and Controls Documentationpp. 301-827.\nAvailable at:  https:\/\/www.fda.gov\/media\/70857\/download [Accessed: July 24, 2017]2002","journal-title":"Spray and Inhalation Solution"},{"key":"ref=17","unstructured":"Guidance for Industry Bioavailability and Bioequivalence\nStudies for Nasal Aerosols and Nasal Sprays for Local Action.\nLocal Action. 2003, 20857 (April), 37. Available at:  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioavailability-and-bioequivalence-studies-nasal-aerosols-and-nasal-sprays-local-action [Accessed:\nJuly 24, 2017]."},{"key":"ref=18","unstructured":"EMEA\/CHMP, 2009, ICH Topic Q 8 (R2) Pharmaceutical\nDevelopment, Step 5: Note for Guidance on Pharmaceutical\nDevelopment. Available at:  [Accessed:\nJul 24,2017]."},{"key":"ref=19","unstructured":"EMA\/CHMP, 2014, ICH Guideline Q9 on Quality Risk\nManagement. Available from:  [Accessed:\nJul 24, 2017]."},{"key":"ref=20","unstructured":"EMA\/CHMP, 2014, ICH Guideline Q10 on Pharmaceutical\nQuality System. Available from:  [Accessed:\nJul 24,2017]."},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/jps.20318","volume":"94","author":"Graff C.L.","year":"2005","unstructured":"Graff C.L.; Pollack G.M.; Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 2005,94(6),1187-1195","journal-title":"J Pharm Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","volume":"237","author":"Kapoor M.","year":"2016","unstructured":"Kapoor M.; Cloyd J.C.; Siegel R.A.; A review of intranasal formulations for the treatment of seizure emergencies. J Control Release 2016,237,147-159","journal-title":"J Control Release"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","volume":"7","author":"Arora P.","year":"2002","unstructured":"Arora P.; Sharma S.; Garg S.; Permeability issues in nasal drug delivery. Drug Discov Today 2002,7(18),967-975","journal-title":"Drug Discov Today"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","volume":"30","author":"Chapman C.D.","year":"2013","unstructured":"Chapman C.D.; Frey W.H.; Craft S.; Danielyan L.; Hallschmid M.; Schi\u00f6th H.B.; Benedict C.; Intranasal treatment of central nervous system dysfunction in humans. Pharm Res 2013,30(10),2475-2484","journal-title":"Pharm Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cne.902160305","volume":"216","author":"Luskin M.B.","year":"1983","unstructured":"Luskin M.B.; Price J.L.; The topographic organization of associational fibers of the olfactory system in the rat, including centrifugal fibers to the olfactory bulb. J Comp Neurol 1983,216(3),264-291","journal-title":"J Comp Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1089\/jam.2006.19.92","volume":"19","author":"Illum L.","year":"2006","unstructured":"Illum L.; Nasal clearance in health and disease. J Aerosol Med 2006,19(1),92-99","journal-title":"J Aerosol Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(97)00058-6","volume":"29","author":"Dahl R.","year":"1998","unstructured":"Dahl R.; Mygind N.; Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev 1998,29(1-2),3-12","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ejps.2006.11.018","volume":"30","author":"Charlton S.","year":"2007","unstructured":"Charlton S.; Jones N.S.; Davis S.S.; Illum L.; Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device. Eur J Pharm Sci 2007,30(3-4),295-302","journal-title":"Eur J Pharm Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1634\/stemcells.2007-0891","volume":"26","author":"Iwai N.","year":"2008","unstructured":"Iwai N.; Zhou Z.; Roop D.R.; Behringer R.R.; Horizontal basal cells are multipotent progenitors in normal and injured adult olfactory epithelium. Stem Cells 2008,26(5),1298-1306","journal-title":"Stem Cells"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"Lochhead J.J.","year":"2012","unstructured":"Lochhead J.J.; Thorne R.G.; Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012,64(7),614-628","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0169-409X(97)00067-7","volume":"29","author":"Vidgren M.T.","year":"1998","unstructured":"Vidgren M.T.; Kublik H.; Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998,29(1-2),157-177","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1021\/mp100029t","volume":"7","author":"Johnson N.J.","year":"2010","unstructured":"Johnson N.J.; Hanson L.R.; Frey W.H.; Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm 2010,7(3),884-893","journal-title":"Mol Pharm"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijpharm.2016.11.055","volume":"517","author":"Menzel C.","year":"2017","unstructured":"Menzel C.; Jelkmann M.; Laffleur F.; Bernkop-Schn\u00fcrch A.; Nasal drug delivery: design of a novel mucoadhesive and in situ gelling polymer. Int J Pharm 2017,517(1-2),196-202","journal-title":"Int J Pharm"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jconrel.2012.05.040","volume":"161","author":"Kammona O.","year":"2012","unstructured":"Kammona O.; Kiparissides C.; Recent advances in nanocarrier-based mucosal delivery of biomolecules. J Control Release 2012,161(3),781-794","journal-title":"J Control Release"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2174\/1567201811666140321113555","volume":"11","author":"Badhan R.K.S.","year":"2014","unstructured":"Badhan R.K.S.; Kaur M.; Lungare S.; Obuobi S.; Improving brain drug targeting through exploitation of the nose-to-brain route: a physiological and pharmacokinetic perspective. Curr Drug Deliv 2014,11(4),458-471","journal-title":"Curr Drug Deliv"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","volume":"337","author":"Costantino H.R.","year":"2007","unstructured":"Costantino H.R.; Illum L.; Brandt G.; Johnson P.H.; Quay S.C.; Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007,337(1-2),1-24","journal-title":"Int J Pharm"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000321044","volume":"40","author":"Bitter C.","year":"2011","unstructured":"Bitter C.; Suter-Zimmermann K.; Surber C.; Nasal drug delivery in humans. Curr Probl Dermatol 2011,40(c),20-35","journal-title":"Curr Probl Dermatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","volume":"134","author":"Grassin-Delyle S.","year":"2012","unstructured":"Grassin-Delyle S.; Buenestado A.; Naline E.; Faisy C.; Blouquit-Laye S.; Couderc L.J.; Le Guen M.; Fischler M.; Devillier P.; Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther 2012,134(3),366-379","journal-title":"Pharmacol Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.22270\/jddt.v2i3.163","volume":"2","year":"2012","unstructured":"Singh; A, Singh; A, Madiv, N. Nasal cavity: a promising transmucosal platform for drug delivery and research approaches from nasal to brain targeting. J Drug Deliv Ther 2012,2(3),22-33","journal-title":"J Drug Deliv Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1248\/bpb.b14-00398","volume":"38","author":"Gizurarson S.","year":"2015","unstructured":"Gizurarson S.; The effect of cilia and the mucociliary clearance on successful drug delivery. Biol Pharm Bull 2015,38(4),497-506","journal-title":"Biol Pharm Bull"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1034\/j.1399-6576.2002.460702.x","volume":"46","author":"Dale O.","year":"2002","unstructured":"Dale O.; Hjortkjaer R.; Kharasch E.D.; Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002,46(7),759-770","journal-title":"Acta Anaesthesiol Scand"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/00005537-200104000-00008","volume":"111","author":"Merkus P.","year":"2001","unstructured":"Merkus P.; Romeijn S.G.; Verhoef J.C.; Merkus F.W.; Schouwenburg P.F.; Classification of cilio-inhibiting effects of nasal drugs. Laryngoscope 2001,111(4 Pt 1),595-602","journal-title":"Laryngoscope"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0169-409X(93)90015-V","volume":"11","author":"Gizurarson S.","year":"1993","unstructured":"Gizurarson S.; The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev 1993,11(3),329-347","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2165\/00137696-200301020-00004","volume":"1","author":"Homer J.J.","year":"2003","unstructured":"Homer J.J.; Aggarwal R.; Cordoza A.; Delivery of topical nasal drugs. Am J Drug Deliv 2003,1(2),125-131","journal-title":"Am J Drug Deliv"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1081-1206(10)62271-5","volume":"84","author":"St\u00e5hl E.","year":"2000","unstructured":"St\u00e5hl E.; van Rompay W.; Wang E.C.; Thomson D.M.; Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 2000,84(4),397-402","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1208\/s12248-013-9494-2","volume":"15","author":"Li B.V.","year":"2013","unstructured":"Li B.V.; Jin F.; Lee S.L.; Bai T.; Chowdhury B.; Caramenico H.T.; Conner D.P.; Bioequivalence for locally acting nasal spray and nasal aerosol products: standard development and generic approval. AAPS J 2013,15(3),875-883","journal-title":"AAPS J"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1592\/phco.22.16.1458.33692","volume":"22","author":"Trangsrud A.J.","year":"2002","unstructured":"Trangsrud A.J.; Whitaker A.L.; Small R.E.; Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 2002,22(11),1458-1467","journal-title":"Pharmacotherapy"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.clinthera.2009.01.016","volume":"31","author":"Shah S.R.","year":"2009","unstructured":"Shah S.R.; Nayak A.; Ratner P.; Roland P.; Wall G.M.; Effects of olopatadine hydrochloride nasal spray 0. 6% in the treatment of seasonal allergic rhinitis\u202f: a phase III, controlled study in adolescents and adults. Clin Ther 2009,31(1),99-107","journal-title":"Clin Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/B:PHAR.0000026823.82950.ff","volume":"26","author":"T\u00fcrker S.","year":"2004","unstructured":"T\u00fcrker S.; Onur E.; \u00d3zer Y.; Nasal route and drug delivery systems. Pharm World Sci 2004,26(3),137-142","journal-title":"Pharm World Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1567201053586047","volume":"2","author":"Vyas T.K.","year":"2005","unstructured":"Vyas T.K.; Shahiwala A.; Marathe S.; Misra A.; Intranasal drug delivery for brain targeting. Curr Drug Deliv 2005,2(2),165-175","journal-title":"Curr Drug Deliv"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1208\/s12248-015-9719-7","volume":"17","author":"Meredith E.","year":"2015","unstructured":"Meredith E.; Salameh T.S.; Banks W.A.; Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. AAPS J 2015,17(4),780-787","journal-title":"AAPS J"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3109\/1061186X.2010.523790","volume":"18","author":"Jabbal-Gill I.","year":"2010","unstructured":"Jabbal-Gill I.; Nasal vaccine innovation. J Drug Target 2010,18(10),771-786","journal-title":"J Drug Target"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17425247.2016.1206074","volume":"14","author":"Thwala L.N.","year":"2017","unstructured":"Thwala L.N.; Pr\u00e9at V.; Csaba N.S.; Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes. Expert Opin Drug Deliv 2017,14(1),23-36","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1526-4610.2005.05004.x","volume":"45","author":"Gawel M.","year":"2005","unstructured":"Gawel M.; Aschoff J.; May A.; Charlesworth B.R.; Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study. Headache 2005,45(1),7-16","journal-title":"Headache"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2165\/00023210-200519020-00003","volume":"19","author":"Dodick D.","year":"2005","unstructured":"Dodick D.; Brandes J.; Elkind A.; Mathew N.; Rodichok L.; Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 2005,19(2),125-136","journal-title":"CNS Drugs"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/head.12905","volume":"56","author":"Munjal S.","year":"2016","unstructured":"Munjal S.; Gautam A.; Offman E.; Brand-Schieber E.; Allenby K.; Fisher D.M.; A randomized trial comparing the pharmacokinetics, safety, and tolerability of DFN-02, an intranasal sumatriptan spray containing a permeation enhancer, with intranasal and subcutaneous sumatriptan in healthy adults. Headache 2016,56(9),1455-1465","journal-title":"Headache"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1526-4610.2006.00339.x","volume":"46","author":"Winner P.","year":"2006","unstructured":"Winner P.; Rothner A.D.; Wooten J.D.; Webster C.; Ames M.; Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache 2006,46(2),212-222","journal-title":"Headache"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0011-393X(05)80180-8","volume":"55","author":"Abboud T.K.","year":"1994","unstructured":"Abboud T.K.; Zhu J.; Longhitano M.; Minehart M.; Mantilla M.; Chu G.; Kimball S.; Rodriguez J.; Terrasi J.; Gangolli J.; Efficacy and safety of butorphanol nasal spray for the relief of postepisiotomy pain. Curr Ther Res Clin Exp 1994,55(5),500-509","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3109\/10717544.2012.762435","volume":"20","author":"Nave R.","year":"2013","unstructured":"Nave R.; Schmitt H.; Popper L.; Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects. Drug Deliv 2013,20(5),216-223","journal-title":"Drug Deliv"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12020-015-0637-3","volume":"51","author":"Nozaki A.","year":"2016","unstructured":"Nozaki A.; Ando T.; Akazawa S.; Satoh T.; Sagara I.; Horie I.; Imaizumi M.; Usa T.; Yanagisawa R.T.; Kawakami A.; Quality of life in the patients with central diabetes insipidus assessed by nagasaki diabetes insipidus questionnaire. Endocrine 2016,51(1),140-147","journal-title":"Endocrine"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0301-2115(01)00297-4","volume":"103","author":"El-Nemr A.","year":"2002","unstructured":"El-Nemr A.; Bhide M.; Khalifa Y.; Al-Mizyen E.; Gillott C.; Lower A.M.; Al-Shawaf T.; Grudzinskas J.G.; Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study. Eur J Obstet Gynecol Reprod Biol 2002,103(2),140-145","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1208\/s12248-014-9596-5","volume":"16","author":"Kapoor M.","year":"2014","unstructured":"Kapoor M.; Winter T.; Lis L.; Georg G.I.; Siegel R.A.; Rapid delivery of diazepam from supersaturated solutions prepared using prodrug\/enzyme mixtures: toward intranasal treatment of seizure emergencies. AAPS J 2014,16(3),577-585","journal-title":"AAPS J"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2146\/ajhp140630","volume":"72","author":"Corrigan M.","year":"2015","unstructured":"Corrigan M.; Wilson S.S.; Hampton J.; Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings. Am J Health Syst Pharm 2015,72(18),1544-1554","journal-title":"Am J Health Syst Pharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1212\/WNL.0b013e3182824e66","volume":"80","author":"Afridi S.K.","year":"2013","unstructured":"Afridi S.K.; Giffin N.J.; Kaube H.; Goadsby P.J.; A ran-domized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 2013,80(7),642-647","journal-title":"Neurology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.annemergmed.2014.09.024","volume":"65","author":"Graudins A.","year":"2015","unstructured":"Graudins A.; Meek R.; Egerton-Warburton D.; Oakley E.; Seith R.; The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries. Ann Emerg Med 2015,65(3),248-254.e1","journal-title":"Ann Emerg Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/S0885-3924(02)00522-5","volume":"24","author":"Pavis H.","year":"2002","unstructured":"Pavis H.; Wilcock A.; Edgecombe J.; Carr D.; Manderson C.; Church A.; Fisher A.; Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer. J Pain Symptom Manage 2002,24(6),598-602","journal-title":"J Pain Symptom Manage"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.ajem.2012.02.019","volume":"30","author":"Steenblik J.","year":"2012","unstructured":"Steenblik J.; Goodman M.; Davis V.; Gee C.; Hopkins C.L.; Stephen R.; Madsen T.; Intranasal sufentanil for the treatment of acute pain in a winter resort clinic. Am J Emerg Med 2012,30(9),1817-1821","journal-title":"Am J Emerg Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"Pardridge W.M.","year":"2005","unstructured":"Pardridge W.M.; The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005,2(1),3-14","journal-title":"NeuroRx"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jpainsymman.2012.09.001","volume":"44","author":"Howard P.","year":"2012","unstructured":"Howard P.; Twycross R.; Shuster J.; Mihalyo M.; Wilcock A.; Antidepressant drugs. J Pain Symptom Manage 2012,44(5),763-783","journal-title":"J Pain Symptom Manage"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/03008870310009650","volume":"106","author":"Antinori A.","year":"2003","unstructured":"Antinori A.; Cingolani A.; Giancola M.L.; Forbici F.; De Luca A.; Perno C.F.; Clinical implications of HIV-1 drug resistance in the neurological compartment. Scand J Infect Dis Suppl 2003,106,41-44","journal-title":"Scand J Infect Dis Suppl"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s13346-012-0085-z","volume":"3","author":"Zaman M.","year":"2013","unstructured":"Zaman M.; Chandrudu S.; Toth I.; Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res 2013,3(1),100-109","journal-title":"Drug Deliv Transl Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00428-003-0898-8","volume":"444","author":"Fujimura Y.","year":"2004","unstructured":"Fujimura Y.; Takeda M.; Ikai H.; Haruma K.; Akisada T.; Harada T.; Sakai T.; Ohuchi M.; The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling. Virchows Arch 2004,444(1),36-42","journal-title":"Virchows Arch"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0169-409X(01)00162-4","volume":"51","author":"Davis S.S.","year":"2001","unstructured":"Davis S.S.; Nasal vaccines. Adv Drug Deliv Rev 2001,51(1-3),21-42","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.coi.2011.03.009","volume":"23","author":"Lawson L.B.","year":"2011","unstructured":"Lawson L.B.; Norton E.B.; Clements J.D.; Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011,23(3),414-420","journal-title":"Curr Opin Immunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jps.21493","volume":"98","author":"Sharma S.","year":"2009","unstructured":"Sharma S.; Mukkur T.K.S.; Benson H.A.E.; Chen Y.; Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 2009,98(3),812-843","journal-title":"J Pharm Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.tox.2008.09.014","volume":"254","author":"Wang J.","year":"2008","unstructured":"Wang J.; Liu Y.; Jiao F.; Lao F.; Li W.; Gu Y.; Li Y.; Ge C.; Zhou G.; Li B.; Zhao Y.; Chai Z.; Chen C.; Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO(2) nanoparticles. Toxicology 2008,254(1-2),82-90","journal-title":"Toxicology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.2174\/0929867321666140716103130","volume":"21","author":"Ong W-Y.","year":"2014","unstructured":"Ong W-Y.; Shalini S-M.; Costantino L.; Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. Curr Med Chem 2014,21(37),4247-4256","journal-title":"Curr Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/IJN.S596","volume":"3","author":"De Jong W.H.","year":"2008","unstructured":"De Jong W.H.; Borm P.J.; Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 2008,3(2),133-149","journal-title":"Int J Nanomedicine"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.drudis.2010.02.009","volume":"16","author":"Chen H.","year":"2011","unstructured":"Chen H.; Khemtong C.; Yang X.; Chang X.; Gao J.; Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 2011,16(7-8),354-360","journal-title":"Drug Discov Today"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0378-5173(99)00463-9","volume":"197","author":"Milhem O.M.","year":"2000","unstructured":"Milhem O.M.; Myles C.; McKeown N.B.; Attwood D.; D\u2019Emanuele A.; Polyamidoamine starburst dendrimers as solubility enhancers. Int J Pharm 2000,197(1-2),239-241","journal-title":"Int J Pharm"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijpharm.2004.07.006","volume":"284","author":"Devarakonda B.","year":"2004","unstructured":"Devarakonda B.; Hill R.A.; de Villiers M.M.; The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine. Int J Pharm 2004,284(1-2),133-140","journal-title":"Int J Pharm"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/(SICI)1521-3765(19990503)5:5<1440:AID-CHEM1440>3.0.CO;2-M","volume":"5","author":"Pistolis G.","year":"1999","unstructured":"Pistolis G.; Malliaris A.; Tsiourvas D.; Paleos C.M.; \n                        Poly (propyleneimine) dendrimers as pH-sensitive controlled-release systems. Chemistry 1999,5,1440-1444","journal-title":"Chemistry"},{"key":"ref=83","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/801820","volume":"2014","author":"Shrestha H.","year":"2014","unstructured":"Shrestha H.; Bala R.; Arora S.; Lipid-based drug delivery systems. J Pharm 2014,2014","journal-title":"J Pharm"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijpharm.2006.02.031","volume":"316","author":"Cui F.","year":"2006","unstructured":"Cui F.; Qian F.; Yin C.; Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int J Pharm 2006,316(1-2),154-161","journal-title":"Int J Pharm"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ddtec.2005.05.008","volume":"2","author":"Issa M.M.","year":"2005","unstructured":"Issa M.M.; K\u00f6ping-H\u00f6gg\u00e5rd M.; Artursson P.; Chitosan and the mucosal delivery of biotechnology drugs. Drug Discov Today Technol 2005,2(1),1-6","journal-title":"Drug Discov Today Technol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1208\/s12248-009-9169-1","volume":"12","author":"Pawar D.","year":"2010","unstructured":"Pawar D.; Goyal A.K.; Mangal S.; Mishra N.; Vaidya B.; Tiwari S.; Jain A.K.; Vyas S.P.; Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J 2010,12(2),130-137","journal-title":"AAPS J"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1016\/j.biomaterials.2006.01.038","volume":"27","author":"Gao X.","year":"2006","unstructured":"Gao X.; Tao W.; Lu W.; Zhang Q.; Zhang Y.; Jiang X.; Fu S.; Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 2006,27(18),3482-3490","journal-title":"Biomaterials"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2016.04.014","volume":"232","author":"Bernocchi B.","year":"2016","unstructured":"Bernocchi B.; Carpentier R.; Lantier I.; Ducournau C.; Dimier-Poisson I.; Betbeder D.; Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles. J Control Release 2016,232,42-50","journal-title":"J Control Release"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1248\/bpb.16.457","volume":"16","author":"Kato Y.","year":"1993","unstructured":"Kato Y.; Hosokawa T.; Hayakawa E.; Ito K.; Influence of liposomes on tryptic digestion of insulin. Biol Pharm Bull 1993,16(5),457-461","journal-title":"Biol Pharm Bull"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s13346-013-0133-3","volume":"3","author":"Shah L.","year":"2013","unstructured":"Shah L.; Yadav S.; Amiji M.; Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv Transl Res 2013,3(4),336-351","journal-title":"Drug Deliv Transl Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1021\/mp070024d","volume":"4","author":"Chavanpatil M.D.","year":"2007","unstructured":"Chavanpatil M.D.; Khdair A.; Gerard B.; Bachmeier C.; Miller D.W.; Shekhar M.P.V.; Panyam J.; Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm 2007,4(5),730-738","journal-title":"Mol Pharm"},{"key":"ref=92","first-page":"6","volume":"3","year":"2011","unstructured":"Rahisuddin; Sharma, P. K.; Garg, G.; Salim, M. Review on nasal drug delivery system with recent advancemnt. Int J Pharm Pharm Sci 2011,3(Suppl. 2),6-11","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=93","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/21\/12\/125102","volume":"21","author":"Anantachaisilp S.","year":"2010","unstructured":"Anantachaisilp S.; Smith S.M.; Treetong A.; Pratontep S.; Puttipipatkhachorn S.; Ruktanonchai U.R.; Chemical and structural investigation of lipid nanoparticles: drug-lipid interaction and molecular distribution. Nanotechnology 2010,21(12)","journal-title":"Nanotechnology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/nano5031351","volume":"5","author":"Shin S.W.","year":"2015","unstructured":"Shin S.W.; Song I.H.; Um S.H.; Role of physicochemical properties in nanoparticle toxicity. Nanomaterials (Basel) 2015,5(3),1351-1365","journal-title":"Nanomaterials (Basel)"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/10611860400015936","volume":"12","author":"Lockman P.R.","year":"2004","unstructured":"Lockman P.R.; Koziara J.M.; Mumper R.J.; Allen D.D.; Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004,12(9-10),635-641","journal-title":"J Drug Target"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.addr.2004.09.004","volume":"57","author":"Alpar H.O.","year":"2005","unstructured":"Alpar H.O.; Somavarapu S.; Atuah K.N.; Bramwell V.W.; Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005,57(3),411-430","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics10010034","volume":"10","author":"Sonvico F.","year":"2018","unstructured":"Sonvico F.; Clementino A.; Buttini F.; Colombo G.; Pescina S.; Stanis\u00e7uaski Guterres S.; Raffin Pohlmann A.; Nicoli S.; Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics 2018,10(1),1-34","journal-title":"Pharmaceutics"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/10611860108997935","volume":"9","author":"Brooking J.","year":"2001","unstructured":"Brooking J.; Davis S.S.; Illum L.; Transport of nanoparticles across the rat nasal mucosa. J Drug Target 2001,9(4),267-279","journal-title":"J Drug Target"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0142-9612(86)90091-8","volume":"7","author":"Kawaguchi H.","year":"1986","unstructured":"Kawaguchi H.; Koiwai N.; Ohtsuka Y.; Miyamoto M.; Sasakawa S.; Phagocytosis of latex particles by leucocytes. I. Dependence of phagocytosis on the size and surface potential of particles. Biomaterials 1986,7(1),61-66","journal-title":"Biomaterials"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijpharm.2015.12.046","volume":"499","author":"Gartziandia O.","year":"2016","unstructured":"Gartziandia O.; Egusquiaguirre S.P.; Bianco J.; Pedraz J.L.; Igartua M.; Hernandez R.M.; Pr\u00e9at V.; Beloqui A.; Nanoparticle transport across in vitro olfactory cell monolayers. Int J Pharm 2016,499(1-2),81-89","journal-title":"Int J Pharm"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1021\/acs.molpharmaceut.5b00088","volume":"12","author":"Mistry A.","year":"2015","unstructured":"Mistry A.; Stolnik S.; Illum L.; Nose-to-brain delivery: investigation of the transport of nanoparticles with different surface characteristics and sizes in excised porcine olfactory epithelium. Mol Pharm 2015,12(8),2755-2766","journal-title":"Mol Pharm"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1039\/C6NR07581A","volume":"9","author":"Ahmad E.","year":"2017","unstructured":"Ahmad E.; Feng Y.; Qi J.; Fan W.; Ma Y.; He H.; Xia F.; Dong X.; Zhao W.; Lu Y.; Wu W.; Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale 2017,9(3),1174-1183","journal-title":"Nanoscale"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.0801763105","volume":"105","author":"Gratton S.E.A.","year":"2008","unstructured":"Gratton S.E.A.; Ropp P.A.; Pohlhaus P.D.; Luft J.C.; Madden V.J.; Napier M.E.; DeSimone J.M.; The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 2008,105(33),11613-11618","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1021\/nl052396o","volume":"6","author":"Chithrani B.D.","year":"2006","unstructured":"Chithrani B.D.; Ghazani A.A.; Chan W.C.W.; Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006,6(4),662-668","journal-title":"Nano Lett"},{"key":"ref=105","doi-asserted-by":"publisher","DOI":"10.1103\/PhysRevE.78.061914","volume":"78","author":"Shi W.","year":"2008","unstructured":"Shi W.; Wang J.; Fan X.; Gao H.; Size and shape effects on diffusion and absorption of colloidal particles near a partially absorbing sphere: implications for uptake of nanoparticles in animal cells. Phys Rev E Stat Nonlin Soft Matter Phys 2008,78(6 Pt 1)","journal-title":"Phys Rev E Stat Nonlin Soft Matter Phys"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.1016\/j.biomaterials.2010.06.051","volume":"31","author":"Qiu Y.","year":"2010","unstructured":"Qiu Y.; Liu Y.; Wang L.; Xu L.; Bai R.; Ji Y.; Wu X.; Zhao Y.; Li Y.; Chen C.; Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. Biomaterials 2010,31(30),7606-7619","journal-title":"Biomaterials"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1021\/nl070363y","volume":"7","author":"Chithrani B.D.","year":"2007","unstructured":"Chithrani B.D.; Chan W.C.W.; Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007,7(6),1542-1550","journal-title":"Nano Lett"},{"key":"ref=108","first-page":"51","volume":"9","author":"Oh N.","year":"2014","unstructured":"Oh N.; Park J.H.; Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomedicine 2014,9(Suppl. 1),51-63","journal-title":"Int J Nanomedicine"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.colsurfb.2007.04.009","volume":"59","author":"Gan Q.","year":"2007","unstructured":"Gan Q.; Wang T.; Chitosan nanoparticle as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces 2007,59(1),24-34","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","volume":"61","author":"Lai S.K.","year":"2009","unstructured":"Lai S.K.; Wang Y.Y.; Hanes J.; Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009,61(2),158-171","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ajps.2014.12.007","volume":"10","author":"Liu M.","year":"2014","unstructured":"Liu M.; Zhang J.; Shan W.; Huang Y.; Developments of mucus penetrating nanoparticles. Asian J Pharm Sci 2014,10(4),275-282","journal-title":"Asian J Pharm Sci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1089\/0894268041457183","volume":"17","author":"Vila A.","year":"2004","unstructured":"Vila A.; S\u00e1nchez A.; Evora C.; Soriano I.; Vila Jato J.L.; Alonso M.J.; PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med 2004,17(2),174-185","journal-title":"J Aerosol Med"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lfs.2016.08.033","volume":"163","author":"Narayan R.","year":"2016","unstructured":"Narayan R.; Singh M.; Ranjan O.; Nayak Y.; Garg S.; Shavi G.V.; Nayak U.Y.; Development of risperidone liposomes for brain targeting through intranasal route. Life Sci 2016,163,38-45","journal-title":"Life Sci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2011.01.007","volume":"78","author":"M\u00fcller R.H.","year":"2011","unstructured":"M\u00fcller R.H.; Gohla S.; Keck C.M.; State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011,78(1),1-9","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejps.2013.03.012","volume":"50","author":"K\u00fcrti L.","year":"2013","unstructured":"K\u00fcrti L.; G\u00e1sp\u00e1r R.; M\u00e1rki \u00c1.; K\u00e1polna E.; Bocsik A.; Veszelka S.; Bartos C.; Ambrus R.; Vastag M.; Deli M.A.; Szab\u00f3-R\u00e9v\u00e9sz P.; \n                        In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration. Eur J Pharm Sci 2013,50(1),86-92","journal-title":"Eur J Pharm Sci"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.colsurfb.2016.08.011","volume":"147","author":"Hao J.","year":"2016","unstructured":"Hao J.; Zhao J.; Zhang S.; Tong T.; Zhuang Q.; Jin K.; Chen W.; Tang H.; Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery. Colloids Surf B Biointerfaces 2016,147,376-386","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1208\/s12249-012-9896-y","volume":"14","author":"Saindane N.S.","year":"2013","unstructured":"Saindane N.S.; Pagar K.P.; Vavia P.R.; Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization. AAPS PharmSciTech 2013,14(1),189-199","journal-title":"AAPS PharmSciTech"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijpharm.2015.06.046","volume":"491","author":"Bartos C.","year":"2015","unstructured":"Bartos C.; Ambrus R.; Sipos P.; Budai-Sz\u0171cs M.; Cs\u00e1nyi E.; G\u00e1sp\u00e1r R.; M\u00e1rki \u00c1.; Seres A.B.; Sztojkov-Ivanov A.; Horv\u00e1th T.; Szab\u00f3-R\u00e9v\u00e9sz P.; Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles. Int J Pharm 2015,491(1-2),198-207","journal-title":"Int J Pharm"},{"key":"ref=119","first-page":"15","volume":"4","author":"Anil P.","year":"2016","unstructured":"Anil P.; Pravin C.; Prashant G.; Amol P.; Prakash B.; Study the effect of surfactant concentration and ultrasonication time on aqueous solubility, particle size and in-vitro drug diffusion of ezogabine nanosuspension by 3 2 factorial designs. Br Biomed Bull 2016,4(1),15-26","journal-title":"Br Biomed Bull"},{"key":"ref=120","first-page":"169","volume":"1","author":"Dilpreet S.","year":"2015","unstructured":"Dilpreet S.; Lipid based drug delivery system: a review. Int J Life Sci Rev 2015,1(5),169-174","journal-title":"Int J Life Sci Rev"},{"key":"ref=121","first-page":"233","volume":"2","author":"Koroleva M.Y.","year":"2016","unstructured":"Koroleva M.Y.; Nagovitsina T.Y.; Bidanov D.A.; Gorbachevski O.S.; Yurtov E.V.; Nano- and microcapsules as drug-delivery systems. Resour Technol 2016,2(4),233-239","journal-title":"Resour Technol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"Akbarzadeh A.","year":"2013","unstructured":"Akbarzadeh A.; Rezaei-Sadabady R.; Davaran S.; Joo S.W.; Zarghami N.; Hanifehpour Y.; Samiei M.; Kouhi M.; Nejati-Koshki K.; Liposome: classification, preparation, and applications. Nanoscale Res Lett 2013,8(1),102","journal-title":"Nanoscale Res Lett"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/jps.1023","volume":"90","author":"Lian T.","year":"2001","unstructured":"Lian T.; Ho R.J.Y.; Trends and developments in liposome drug delivery systems. J Pharm Sci 2001,90(6),667-680","journal-title":"J Pharm Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/10408447809029333","volume":"6","author":"Kimelberg H.K.","year":"1978","unstructured":"Kimelberg H.K.; Mayhew E.G.; Gregoriadis G.; Properties and biological effects of liposomes and their uses in pharmacology and toxicology. Crit Rev Toxicol 1978,6(1),25-79","journal-title":"Crit Rev Toxicol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/02652040010000334","volume":"18","author":"Law S.L.","year":"2001","unstructured":"Law S.L.; Shih C.L.; Characterization of calcitonin-containing liposome formulations for intranasal delivery. J Microencapsul [ST\u2013Characterization of calcitonin\u2013conta2001,18(2),211-221","journal-title":"J Microencapsul"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1081\/LPR-100108460","volume":"11","author":"Law S.L.","year":"2001","unstructured":"Law S.L.; Huang K.J.; Chou V.H.; Cherng J.Y.; Enhancement of nasal absorption of calcitonin loaded in liposomes. J Liposome Res 2001,11(2-3),165-174","journal-title":"J Liposome Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.peptides.2009.03.018","volume":"30","author":"Chen M.","year":"2009","unstructured":"Chen M.; Li X.R.; Zhou Y.X.; Yang K.W.; Chen X.W.; Deng Q.; Liu Y.; Ren L.J.; Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides 2009,30(7),1288-1295","journal-title":"Peptides"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1248\/cpb.40.1569","volume":"40","author":"Maitani Y.","year":"1992","unstructured":"Maitani Y.; Asano S.; Takahashi S.; Nakagaki M.; Nagai T.; Permeability of insulin entrapped in liposome through the nasal mucosa of rabbits. Chem Pharm Bull (Tokyo) 1992,40(6),1569-1572","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1081\/DDC-100102275","volume":"25","author":"Muramatsu K.","year":"1999","unstructured":"Muramatsu K.; Maitani Y.; Takayama K.; Nagai T.; The relationship between the rigidity of the liposomal membrane and the absorption of insulin after nasal administration of liposomes modified with an enhancer containing insulin in rabbits. Drug Dev Ind Pharm 1999,25(10),1099-1105","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/10611860701453653","volume":"15","author":"Jain A.K.","year":"2007","unstructured":"Jain A.K.; Chalasani K.B.; Khar R.K.; Ahmed F.J.; Diwan P.V.; Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target 2007,15(6),417-427","journal-title":"J Drug Target"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","volume":"88","author":"Fortuna A.","year":"2014","unstructured":"Fortuna A.; Alves G.; Serralheiro A.; Sousa J.; Falc\u00e3o A.; Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. Eur J Pharm Biopharm 2014,88(1),8-27","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/jps.21939","volume":"99","author":"Migliore M.M.","year":"2010","unstructured":"Migliore M.M.; Vyas T.K.; Campbell R.B.; Amiji M.M.; Waszczak B.L.; Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 2010,99(4),1745-1761","journal-title":"J Pharm Sci"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"8622","DOI":"10.1016\/j.vaccine.2007.09.042","volume":"25","author":"Patel G.B.","year":"2007","unstructured":"Patel G.B.; Zhou H.; Ponce A.; Chen W.; Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine 2007,25(51),8622-8636","journal-title":"Vaccine"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0264-410X(95)93129-W","volume":"13","author":"de Haan A.","year":"1995","unstructured":"de Haan A.; De; Geerligs, H. J.; Huchshorn, J. P.; Scharrenburg van, G.; Palache, A.; Wilsch, J. Mucosal immunoadjuvant activity of liposomes: induction of systemic igg and secretory IGA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 1995,13(2),155-162","journal-title":"Vaccine"},{"key":"ref=135","first-page":"123","volume":"77","author":"Wong J.P.","year":"1992","unstructured":"Wong J.P.; Cherwonogrodzky J.W.; Di Ninno V.L.; Stadnyk L.L.; Knodel M.H.; Liposome potentiation of humoral immune response to lipopolysaccharide and o-polysaccharide antigens of Brucella Abortus. Immunology 1992,77(1),123-128","journal-title":"Immunology"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1016\/j.actbio.2012.11.007","volume":"9","author":"Wang H.W.","year":"2013","unstructured":"Wang H.W.; Jiang P.L.; Lin S.F.; Lin H.J.; Ou K.L.; Deng W.P.; Lee L.W.; Huang Y.Y.; Liang P.H.; Liu D.Z.; Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization. Acta Biomater 2013,9(3),5681-5688","journal-title":"Acta Biomater"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/j.vaccine.2008.02.058","volume":"26","author":"Khatri K.","year":"2008","unstructured":"Khatri K.; Goyal A.K.; Gupta P.N.; Mishra N.; Mehta A.; Vyas S.P.; Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008,26(18),2225-2233","journal-title":"Vaccine"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1016\/j.biomaterials.2007.03.028","volume":"28","author":"Lu Y.","year":"2007","unstructured":"Lu Y.; Kawakami S.; Yamashita F.; Hashida M.; Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials 2007,28(21),3255-3262","journal-title":"Biomaterials"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"M\u00fcller R.H.","year":"2000","unstructured":"M\u00fcller R.H.; M\u00e4der K.; Gohla S.; Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000,50(1),161-177","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s13346-012-0105-z","volume":"3","author":"Chavan S.S.","year":"2013","unstructured":"Chavan S.S.; Ingle S.G.; Vavia P.R.; Preparation and characterization of solid lipid nanoparticle-based nasal spray of budesonide. Drug Deliv Transl Res 2013,3(5),402-408","journal-title":"Drug Deliv Transl Res"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s13346-012-0110-2","volume":"2","author":"Singh A.P.","year":"2012","unstructured":"Singh A.P.; Saraf S.K.; Saraf S.A.; SLN approach for nose-to-brain delivery of alprazolam. Drug Deliv Transl Res 2012,2(6),498-507","journal-title":"Drug Deliv Transl Res"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2147\/DDDT.S102500","volume":"11","author":"Fatouh A.M.","year":"2017","unstructured":"Fatouh A.M.; Elshafeey A.H.; Abdelbary A.; Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des Devel Ther 2017,11,1815-1825","journal-title":"Drug Des Devel Ther"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1021\/acs.molpharmaceut.6b00586","volume":"13","author":"Khan A.","year":"2016","unstructured":"Khan A.; Imam S.S.; Aqil M.; Ahad A.; Sultana Y.; Ali A.; Khan K.; Brain Targeting of Temozolomide via the Intranasal Route Using Lipid-Based Nanoparticles: Brain Pharmacokinetic and Scintigraphic Analyses. Mol Pharm 2016,13(11),3773-3782","journal-title":"Mol Pharm"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ejpb.2017.04.009","volume":"117","author":"Hommoss G.","year":"2017","unstructured":"Hommoss G.; Pyo S.M.; M\u00fcller R.H.; Mucoadhesive tetrahydrocannabinol-loaded NLC - Formulation optimization and long-term physicochemical stability. Eur J Pharm Biopharm 2017,117,408-417","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=145","first-page":"1671","volume":"32","author":"Bagheri A.","year":"2014","unstructured":"Bagheri A.; Chu B.S.; Yaakob H.; Niosomal drug delivery systems: formulation, preparation and applications. World Appl Sci J 2014,32(8),1671-1685","journal-title":"World Appl Sci J"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/10717544.2013.838077","volume":"21","author":"Abdelkader H.","year":"2013","unstructured":"Abdelkader H.; Alani A.W.G.; Alany R.G.; Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv 2013,21(2),87-100","journal-title":"Drug Deliv"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/15701638113109990031","volume":"10","author":"Ravouru N.","year":"2013","unstructured":"Ravouru N.; Kondreddy P.; Korakanchi D.; Haritha M.; Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting. Curr Drug Discov Technol 2013,10(4),270-282","journal-title":"Curr Drug Discov Technol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/10717544.2016.1259371","volume":"24","author":"Ammar H.O.","year":"2017","unstructured":"Ammar H.O.; Haider M.; Ibrahim M.; El Hoffy N.M.; \n                        In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration. Drug Deliv 2017,24(1),414-421","journal-title":"Drug Deliv"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijpharm.2012.06.042","volume":"440","author":"Cortesi R.","year":"2013","unstructured":"Cortesi R.; Ravani L.; Rinaldi F.; Marconi P.; Drechsler M.; Manservigi M.; Argnani R.; Menegatti E.; Esposito E.; Manservigi R.; Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes. Int J Pharm 2013,440(2),229-237","journal-title":"Int J Pharm"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"R635","DOI":"10.1088\/0953-8984\/18\/41\/R01","volume":"18","author":"Mason T.G.","year":"2006","unstructured":"Mason T.G.; Wilking J.N.; Meleson K.; Chang C.B.; Graves S.M.; Nanoemulsions: formation, structure, and physical properties. J Phys Condens Matter 2006,18(41),R635-R666","journal-title":"J Phys Condens Matter"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40005-016-0228-1","volume":"46","author":"Jaiswal M.","year":"2016","unstructured":"Jaiswal M.; Kumar A.; Sharma S.; Nanoemulsions loaded Carbopol\u00ae 934 based gel for intranasal delivery of neuroprotective Centella Asiatica Extract: in-vitro and ex-vivo permeation study. J Pharm Investig 2016,46(1),79-89","journal-title":"J Pharm Investig"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2174\/1568026615666150108144655","volume":"15","author":"Comfort C.","year":"2015","unstructured":"Comfort C.; Garrastazu G.; Pozzoli M.; Sonvico F.; Opportunities and challenges for the nasal administration of nanoemulsions. Curr Top Med Chem 2015,15(4),356-368","journal-title":"Curr Top Med Chem"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1517\/17425247.2013.812069","volume":"10","author":"Hosny K.M.","year":"2013","unstructured":"Hosny K.M.; Banjar Z.M.; The formulation of a nasal nanoemulsion zaleplon in situ gel for the treatment of insomnia. Expert Opin Drug Deliv 2013,10(8),1033-1041","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1016\/S0264-410X(03)00381-5]","volume":"21","author":"Myc A.","year":"2003","unstructured":"Myc A.; Kukowska-Latallo J.F.; Bielinska A.U.; Cao P.; Myc P.P.; Janczak K.; Sturm T.R.; Grabinski M.S.; Landers J.J.; Young K.S.; Chang J.; Hamouda T.; Olszewski M.A.; Baker J.R.; Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 2003,21(25-26),3801-3814","journal-title":"Vaccine"},{"key":"ref=155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021823","volume":"6","author":"Lindell D.M.","year":"2011","unstructured":"Lindell D.M.; Morris S.B.; White M.P.; Kallal L.E.; Lundy P.K.; Hamouda T.; Baker J.R.; Lukacs N.W.; A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS One 2011,6(7)","journal-title":"PLoS One"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/aid.2007.0148","volume":"24","author":"Bielinska A.U.","year":"2008","unstructured":"Bielinska A.U.; Janczak K.W.; Landers J.J.; Markovitz D.M.; Montefiori D.C.; Baker J.R.; Jr Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008,24(2),271-281","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4161\/hv.6.7.11818","volume":"6","author":"Hamouda T.","year":"2010","unstructured":"Hamouda T.; Chepurnov A.; Mank N.; Knowlton J.; Chepurnova T.; Myc A.; Sutcliffe J.; Baker J.R.; Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin 2010,6(7),585-594","journal-title":"Hum Vaccin"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1208\/s12249-008-9178-x","volume":"10","author":"Azeem A.","year":"2009","unstructured":"Azeem A.; Rizwan M.; Ahmad F.J.; Iqbal Z.; Khar R.K.; Aqil M.; Talegaonkar S.; Nanoemulsion components screening and selection: a technical note. AAPS PharmSciTech 2009,10(1),69-76","journal-title":"AAPS PharmSciTech"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.2147\/IJN.S91529","volume":"10","author":"Sun H.","year":"2015","unstructured":"Sun H.; Wei C.; Liu B.; Jing H.; Feng Q.; Tong Y.; Yang Y.; Yang L.; Zuo Q.; Zhang Y.; Zou Q.; Zeng H.; Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine. Int J Nanomedicine 2015,10,7275-7290","journal-title":"Int J Nanomedicine"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3109\/03639049809108571","volume":"24","author":"Quintanar-Guerrero D.","year":"1998","unstructured":"Quintanar-Guerrero D.; All\u00e9mann E.; Fessi H.; Doelker E.; Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 1998,24(12),1113-1128","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1773-2247(06)50061-9","volume":"16","author":"Prego C.","year":"2006","unstructured":"Prego C.; Torres D.; Alonso M.J.; Chitosan nanocapsules: a new carrier for nasal peptide delivery. J Drug Deliv Sci Technol 2006,16(5),331-337","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2147\/IJN.S98547","volume":"11","author":"Sallam M.A.","year":"2016","unstructured":"Sallam M.A.; Helal H.M.; Mortada S.M.; Rationally designed nanocarriers for intranasaltherapy of allergic rhinitis: influence of carrier type on in vivo nasal deposition. Int J Nanomedicine 2016,11,2345-2357","journal-title":"Int J Nanomedicine"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.2147\/IJN.S119033","volume":"11","author":"Clementino A.","year":"2016","unstructured":"Clementino A.; Batger M.; Garrastazu G.; Pozzoli M.; Del Favero E.; Rondelli V.; Gutfilen B.; Barboza T.; Sukkar M.B.; Souza S.A.L.; Cant\u00f9 L.; Sonvico F.; The nasal delivery of nanoencapsulated statins- an approach for brain delivery. Int J Nanomedicine 2016,11,6575-6590","journal-title":"Int J Nanomedicine"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jconrel.2013.09.012","volume":"172","author":"Vicente S.","year":"2013","unstructured":"Vicente S.; Peleteiro M.; D\u00edaz-Freitas B.; Sanchez A.; Gonz\u00e1lez-Fern\u00e1ndez \u00c1.; Alonso M.J.; Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy. J Control Release 2013,172(3),773-781","journal-title":"J Control Release"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","volume":"358","author":"Kumar M.","year":"2008","unstructured":"Kumar M.; Mirsa A.; Mishra A.K.; Mishra P.; Pathak K.; Intranasal nanoemulsion based brain targeting delivery system of risperidone. Int J Pharm 2008,358(1-2),285-291","journal-title":"Int J Pharm"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1080\/10611860802476504","volume":"16","author":"Kumar M.","year":"2008","unstructured":"Kumar M.; Misra A.; Mishra A.K.; Mishra P.; Pathak K.; Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 2008,16(10),806-814","journal-title":"J Drug Target"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijpharm.2018.03.055","volume":"543","author":"Colombo M.","year":"2018","unstructured":"Colombo M.; Figueir\u00f3 F.; de Fraga Dias A.; Teixeira H.F.; Battastini A.M.O.; Koester L.S.; Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro. Int J Pharm 2018,543(1-2),214-223","journal-title":"Int J Pharm"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ijpharm.2017.07.030","volume":"529","author":"Abdou E.M.","year":"2017","unstructured":"Abdou E.M.; Kandil S.M.; Miniawy H.M.F.E.; Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion. Int J Pharm 2017,529(1-2),667-677","journal-title":"Int J Pharm"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3109\/10717544.2015.1092619","volume":"23","author":"Nasr M.","year":"2016","unstructured":"Nasr M.; Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery. Drug Deliv 2016,23(4),1444-1452","journal-title":"Drug Deliv"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/10717540802035251","volume":"15","author":"Alsarra I.A.","year":"2008","unstructured":"Alsarra I.A.; Hamed A.Y.; Alanazi F.K.; Acyclovir liposomes for intranasal systemic delivery: development and pharmacokinetics evaluation. Drug Deliv 2008,15(5),313-321","journal-title":"Drug Deliv"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijpharm.2012.04.007","volume":"430","author":"Qiang F.","year":"2012","unstructured":"Qiang F.; Shin H.J.; Lee B.J.; Han H.K.; Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome. Int J Pharm 2012,430(1-2),161-166","journal-title":"Int J Pharm"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/10717544.2017.1309476","volume":"24","author":"Nageeb El-Helaly S.","year":"2017","unstructured":"Nageeb El-Helaly S.; Abd Elbary A.; Kassem M.A.; El-Nabarawi M.A.; Electrosteric stealth rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. Drug Deliv 2017,24(1),692-700","journal-title":"Drug Deliv"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/DDDT.S113171","volume":"10","author":"Al Asmari A.K.","year":"2016","unstructured":"Al Asmari A.K.; Ullah Z.; Tariq M.; Fatani A.; Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther 2016,10,205-215","journal-title":"Drug Des Devel Ther"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"10001","DOI":"10.1039\/C5RA19113K","volume":"6","author":"Chandra Bhatt P.","year":"2016","unstructured":"Chandra Bhatt P.; Srivastava P.; Pandey P.; Khan W.; Panda B.P.; Nose to brain delivery of astaxanthin-loaded solid lipid nanoparticles: fabrication, radio labeling, optimization and biological studies. RSC Advances 2016,6(12),10001-10010","journal-title":"RSC Advances"},{"key":"ref=175","first-page":"17590","volume":"8","author":"Li J.C.","year":"2015","unstructured":"Li J.C.; Zhang W.J.; Zhu J.X.; Zhu N.; Zhang H.M.; Wang X.; Zhang J.; Wang Q.Q.; Preparation and brain delivery of nasal solid lipid nanoparticles of quetiapine fumarate in situ gel in rat model of schizophrenia. Int J Clin Exp Med 2015,8(10),17590-17600","journal-title":"Int J Clin Exp Med"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","volume":"32","author":"Zheng X.","year":"2015","unstructured":"Zheng X.; Shao X.; Zhang C.; Tan Y.; Liu Q.; Wan X.; Zhang Q.; Xu S.; Jiang X.; Intranasal h102 peptide-loaded liposomes for brain delivery to treat Alzheimer\u2019s Disease. Pharm Res 2015,32(12),3837-3849","journal-title":"Pharm Res"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","volume":"34","author":"Li W.","year":"2012","unstructured":"Li W.; Zhou Y.; Zhao N.; Hao B.; Wang X.; Kong P.; Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol 2012,34(2),272-279","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.neuroscience.2015.07.016","volume":"303","author":"Bender T.S.","year":"2015","unstructured":"Bender T.S.; Migliore M.M.; Campbell R.B.; John Gatley S.; Waszczak B.L.; Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats. Neuroscience 2015,303,569-576","journal-title":"Neuroscience"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuroscience.2014.05.019","volume":"274","author":"Migliore M.M.","year":"2014","unstructured":"Migliore M.M.; Ortiz R.; Dye S.; Campbell R.B.; Amiji M.M.; Waszczak B.L.; Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson\u2019s disease. Neuroscience 2014,274,11-23","journal-title":"Neuroscience"},{"key":"ref=180","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7439.S7-006","author":"Yasir M.","year":"2015","unstructured":"Yasir M.; Sara U.V.S.; Som I.; Haloperidol loaded solid\nlipid nanoparticles for nose to brain delivery: stability and\nin vivo studies. J Nanomed Nanotechnol S7, 006.2015","journal-title":"J Nanomed Nanotechnol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.provac.2009.07.027","volume":"1","author":"Tiwari S.","year":"2009","unstructured":"Tiwari S.; Goyal A.K.; Mishra N.; Vaidya B.; Mehta A.; Dube D.; Vyas S.P.; Liposome in situ gelling system: novel carrier based vaccine adjuvant for intranasal delivery of recombinant protein vaccine. Procedia Vaccinol 2009,1(1),148-163","journal-title":"Procedia Vaccinol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.actbio.2016.04.012","volume":"41","author":"Ghaffar K.A.","year":"2016","unstructured":"Ghaffar K.A.; Marasini N.; Giddam A.K.; Batzloff M.R.; Good M.F.; Skwarczynski M.; Toth I.; Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus. Acta Biomater 2016,41,161-168","journal-title":"Acta Biomater"},{"key":"ref=183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139785","volume":"10","author":"Tada R.","year":"2015","unstructured":"Tada R.; Hidaka A.; Iwase N.; Takahashi S.; Yamakita Y.; Iwata T.; Muto S.; Sato E.; Takayama N.; Honjo E.; Kiyono H.; Kunisawa J.; Aramaki Y.; Intranasal Immunization with DOTAP cationic liposomes combined with DC-cholesterol induces potent antigen-specific mucosal and systemic immune responses in mice. PLoS One 2015,10(10)","journal-title":"PLoS One"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2172-9-38","volume":"9","author":"Rosada R.S.","year":"2008","unstructured":"Rosada R.S.; de la Torre L.G.; Frantz F.G.; Trombone A.P.; Z\u00e1rate-Blad\u00e9s C.R.; Fonseca D.M.; Souza P.R.; Brand\u00e3o I.T.; Masson A.P.; Soares \u00c9.G.; Ramos S.G.; Faccioli L.H.; Silva C.L.; Santana M.H.; Coelho-Castelo A.A.; Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol 2008,9(1),38","journal-title":"BMC Immunol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ejps.2013.07.006","volume":"50","author":"Chen K.H.","year":"2013","unstructured":"Chen K.H.; Di Sabatino M.; Albertini B.; Passerini N.; Kett V.L.; The effect of polymer coatings on physicochemical properties of spray-dried liposomes for nasal delivery of BSA. Eur J Pharm Sci 2013,50(3-4),312-322","journal-title":"Eur J Pharm Sci"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijpharm.2013.11.038","volume":"461","author":"Kumar M.","year":"2014","unstructured":"Kumar M.; Kakkar V.; Mishra A.K.; Chuttani K.; Kaur I.P.; Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood. Int J Pharm 2014,461(1-2),223-233","journal-title":"Int J Pharm"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1016\/j.matpr.2015.10.067","volume":"2","author":"Singh A.","year":"2015","unstructured":"Singh A.; Ubrane R.; Prasad P.; Ramteke S.; Preparation and characterization of rizatriptan benzoate loaded solid lipid nanoparticles for brain targeting. Mater Today Proc 2015,2(9),4521-4543","journal-title":"Mater Today Proc"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jddst.2016.03.008","volume":"33","author":"Shah B.","year":"2016","unstructured":"Shah B.; Khunt D.; Bhatt H.; Misra M.; Padh H.; Intranasal delivery of venlafaxine loaded nanostructured lipid carrier: risk assessment and qbd based optimization*. J Drug Deliv Sci Technol 2016,33,37-50","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1039\/C5RA19793G","volume":"6","author":"Singh S.K.","year":"2016","unstructured":"Singh S.K.; Dadhania P.; Vuddanda P.R.; Jain A.; Velaga S.; Singh S.; intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural Assessment. RSC Advances 2016,6(3),2032-2045","journal-title":"RSC Advances"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1166\/jbn.2015.2078","volume":"11","author":"Fonseca F.N.","year":"2015","unstructured":"Fonseca F.N.; Betti A.H.; Carvalho F.C.; Gremi\u00e3o M.P.D.; Dimer F.A.; Guterres S.S.; Tebaldi M.L.; Rates S.M.K.; Pohlmann A.R.; Mucoadhesive amphiphilic methacrylic copolymer-functionalized poly(\u03b5-caprolactone) nanocapsules for nose-to-brain delivery of olanzapine. J Biomed Nanotechnol 2015,11(8),1472-1481","journal-title":"J Biomed Nanotechnol"},{"key":"ref=191","first-page":"13","volume":"7","author":"Vyshnavi V.","year":"2015","unstructured":"Vyshnavi V.; Indira S.; Prathima S.; Formulation and evaluation of nasal niosomal in situ gels of loratadine. Int J Pharm Sci Drug Res 2015,7(1),13-21","journal-title":"Int J Pharm Sci Drug Res"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4155\/tde-2017-0005","volume":"8","author":"Priprem A.","year":"2017","unstructured":"Priprem A.; Johns J.R.; Limsitthichaikoon S.; Limphirat W.; Mahakunakorn P.; Johns N.P.; Intranasal melatonin nanoniosomes: pharmacokinetic, pharmacodynamics and toxicity studies. Ther Deliv 2017,8(6),373-390","journal-title":"Ther Deliv"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1208\/s12249-016-0552-9","volume":"18","author":"Boche M.","year":"2017","unstructured":"Boche M.; Pokharkar V.; Quetiapine nanoemulsion for intranasal drug delivery: evaluation of brain-targeting efficiency. AAPS PharmSciTech 2017,18(3),686-696","journal-title":"AAPS PharmSciTech"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3109\/10837450.2014.959177","volume":"20","author":"Lalani J.","year":"2015","unstructured":"Lalani J.; Baradia D.; Lalani R.; Misra A.; Brain targeted intranasal delivery of tramadol: comparative study of microemulsion and nanoemulsion. Pharm Dev Technol 2015,20(8),992-1001","journal-title":"Pharm Dev Technol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/21691401.2017.1337024","volume":"46","author":"Ahmad N.","year":"2018","unstructured":"Ahmad N.; Ahmad R.; Naqvi A.A.; Alam M.A.; Ashafaq M.; Abdur Rub R.; Ahmad F.J.; Intranasal delivery of quercetin-loaded mucoadhesive nanoemulsion for treatment of cerebral ischaemia. Artif Cells Nanomed Biotechnol 2018,46(4),717-729","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijbiomac.2016.03.019","volume":"88","author":"Ahmad N.","year":"2016","unstructured":"Ahmad N.; Ahmad R.; Alam M.A.; Samim M.; Iqbal Z.; Ahmad F.J.; Quantification and evaluation of thymoquinone loaded mucoadhesive nanoemulsion for treatment of cerebral ischemia. Int J Biol Macromol 2016,88,320-332","journal-title":"Int J Biol Macromol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3109\/10717544.2013.838014","volume":"21","author":"Mahajan H.S.","year":"2014","unstructured":"Mahajan H.S.; Mahajan M.S.; Nerkar P.P.; Agrawal A.; Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv 2014,21(2),148-154","journal-title":"Drug Deliv"},{"key":"ref=198","first-page":"34","volume":"3","author":"Mishra D.K.","year":"2013","unstructured":"Mishra D.K.; Kumar A.; Raj R.; Chaturvedi A.; Campula MCM based nanoemulsion for intranasal delivery of an antidepressant. Bull Pharm Res 2013,3(1),34-39","journal-title":"Bull Pharm Res"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.nano.2015.12.374","volume":"12","author":"Yadav S.","year":"2016","unstructured":"Yadav S.; Gandham S.K.; Panicucci R.; Amiji M.M.; Intranasal brain delivery of cationic nanoemulsion-encapsulated tnf\u03b1 siRNA in prevention of experimental neuroinflammation. nanomedicine nanotechnology. Biol Med (Aligarh) 2016,12(4),987-1002","journal-title":"Biol Med (Aligarh)"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00430-009-0137-2","volume":"199","author":"Makidon P.E.","year":"2010","unstructured":"Makidon P.E.; Knowlton J.; Groom J.V.; Blanco L.P.; LiPuma, J.J.; Bielinska, A.U.; Baker, J.R., Jr Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med Microbiol Immunol (Berl) 2010,199(2),81-92","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jddst.2015.05.007","volume":"28","author":"Sravanthi V.","year":"2015","unstructured":"Sravanthi V.; Pallavi M.C.P.; Bonam S.R.; Sathyabama S.; Sampath Kumar H.M.; Oleic acid nanoemulsion for nasal vaccination: impact on adjuvanticity based immune response. J Drug Deliv Sci Technol 2015,28,56-63","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1016\/j.vaccine.2012.09.007","volume":"30","author":"Das S.C.","year":"2012","unstructured":"Das S.C.; Hatta M.; Wilker P.R.; Myc A.; Hamouda T.; Neumann G.; Baker J.R.; Kawaoka Y.; Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 2012,30(48),6871-6877","journal-title":"Vaccine"},{"key":"ref=203","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002954","volume":"3","author":"Makidon P.E.","year":"2008","unstructured":"Makidon P.E.; Bielinska A.U.; Nigavekar S.S.; Janczak K.W.; Knowlton J.; Scott A.J.; Mank N.; Cao Z.; Rathinavelu S.; Beer M.R.; Wilkinson J.E.; Blanco L.P.; Landers J.J.; Baker J.R.; Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 2008,3(8)","journal-title":"PLoS One"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2174\/138161210791164108","volume":"16","author":"Ali J.","year":"2010","unstructured":"Ali J.; Ali M.; Baboota S.; Sahani J.K.; Ramassamy C.; Dao L.; Bhavna. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 2010,16(14),1644-1653","journal-title":"Curr Pharm Des"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-3659(00)00339-4","volume":"70","author":"Soppimath K.","year":"2001","unstructured":"Soppimath K.; Aminabhavi; Rudzinski WE, T.; Kulkarni AR. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001,70(1-2),1-20","journal-title":"J Control Release"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.3390\/md8072117","volume":"8","author":"Pangestuti R.","year":"2010","unstructured":"Pangestuti R.; Kim S-K.; Neuroprotective properties of chitosan and its derivatives. Mar Drugs 2010,8(7),2117-2128","journal-title":"Mar Drugs"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3109\/03639045.2013.789051","volume":"40","author":"Sharma S.","year":"2014","unstructured":"Sharma S.; Lohan S.; Murthy R.S.R.; Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm 2014,40(7),869-878","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jconrel.2005.11.014","volume":"111","author":"Amidi M.","year":"2006","unstructured":"Amidi M.; Romeijn S.G.; Borchard G.; Junginger H.E.; Hennink W.E.; Jiskoot W.; Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release 2006,111(1-2),107-116","journal-title":"J Control Release"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3233\/JAD-2009-1092","volume":"17","author":"Imbimbo B.P.","year":"2009","unstructured":"Imbimbo B.P.; Why did tarenflurbil fail in Alzheimer\u2019s disease? J Alzheimers Dis 2009,17(4),757-760","journal-title":"J Alzheimers Dis"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","volume":"92","author":"Muntimadugu E.","year":"2016","unstructured":"Muntimadugu E.; Dhommati R.; Jain A.; Challa V.G.S.; Shaheen M.; Khan W.; Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer\u2019s disease. Eur J Pharm Sci 2016,92,224-234","journal-title":"Eur J Pharm Sci"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1038\/srep05128","volume":"4","author":"Phua K.K.L.","year":"2014","unstructured":"Phua K.K.L.; Staats H.F.; Leong K.W.; Nair S.K.; Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci Rep 2014,4,5128","journal-title":"Sci Rep"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jconrel.2011.03.009","volume":"152","author":"Matsuo K.","year":"2011","unstructured":"Matsuo K.; Koizumi H.; Akashi M.; Nakagawa S.; Fujita T.; Yamamoto A.; Okada N.; Intranasal immunization with poly(\u03b3-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J Control Release 2011,152(2),310-316","journal-title":"J Control Release"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jconrel.2016.02.032","volume":"227","author":"Van Woensel M.","year":"2016","unstructured":"Van Woensel M.; Wauthoz N.; Rosi\u00e8re R.; Mathieu V.; Kiss R.; Lefranc F.; Steelant B.; Dilissen E.; Van Gool S.W.; Mathivet T.; Gerhardt H.; Amighi K.; De Vleeschouwer S.; Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J Control Release 2016,227,71-81","journal-title":"J Control Release"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejmech.2006.07.015","volume":"42","author":"Ma M.","year":"2007","unstructured":"Ma M.; Cheng Y.; Xu Z.; Xu P.; Qu H.; Fang Y.; Xu T.; Wen L.; Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem 2007,42(1),93-98","journal-title":"Eur J Med Chem"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.eurpolymj.2017.03.012","volume":"90","author":"Lancelot A.","year":"2017","unstructured":"Lancelot A.; Claver\u00eda-gimeno R.; Vel\u00e1zquez-campoy A.; Abian O.; Serrano J.L.; Sierra T.; Nanostructures based on ammonium-terminated amphiphilic janus dendrimers as camptothecin carriers with antiviral activity. Eur Polym J 2017,90(March),136-149","journal-title":"Eur Polym J"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1359-6446(04)03276-3","volume":"10","author":"Gillies E.R.","year":"2005","unstructured":"Gillies E.R.; Fr\u00e9chet J.M.J.; Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005,10(1),35-43","journal-title":"Drug Discov Today"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.addr.2005.09.018","volume":"57","author":"Svenson S.","year":"2005","unstructured":"Svenson S.; Tomalia D.A.; Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2005,57(15),2106-2129","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/0975-7406.130965","volume":"6","author":"Madaan K.","year":"2014","unstructured":"Madaan K.; Kumar S.; Poonia N.; Lather V.; Pandita D.; Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci 2014,6(3),139-150","journal-title":"J Pharm Bioallied Sci"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/mt.2011.291","volume":"20","author":"Kim I-D.","year":"2012","unstructured":"Kim I-D.; Shin J-H.; Kim S-W.; Choi S.; Ahn J.; Han P-L.; Park J-S.; Lee J-K.; Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther 2012,20(4),829-839","journal-title":"Mol Ther"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1021\/acs.molpharmaceut.5b00402","volume":"12","author":"Katare Y.K.","year":"2015","unstructured":"Katare Y.K.; Daya R.P.; Sookram Gray C.; Luckham R.E.; Bhandari J.; Chauhan A.S.; Mishra R.K.; Brain targeting of a water insoluble antipsychotic drug haloperidol via the intranasal route using PAMAM dendrimer. Mol Pharm 2015,12(9),3380-3388","journal-title":"Mol Pharm"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijpharm.2010.04.021","volume":"393","author":"Dong Z.","year":"2010","unstructured":"Dong Z.; Katsumi H.; Sakane T.; Yamamoto A.; Effects of polyamidoamine (PAMAM) dendrimers on the nasal absorption of poorly absorbable drugs in rats. Int J Pharm 2010,393(1-2),244-252","journal-title":"Int J Pharm"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.addr.2005.09.019","volume":"57","author":"Duncan R.","year":"2005","unstructured":"Duncan R.; Izzo L.; Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005,57(15),2215-2237","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1098\/rspa.2009.0448","author":"Chauhan A.S.","year":"2009","unstructured":"Chauhan A.S.; Jain N.K.; Diwan P.V.; Pre-clinical and behavioural toxicity profile of PAMAM dendrimers in mice. Proc R Soc A 2009,466","journal-title":"Proc R Soc A"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.toxlet.2014.04.020","volume":"228","author":"Win-Shwe T-T.","year":"2014","unstructured":"Win-Shwe T-T.; Sone H.; Kurokawa Y.; Zeng Y.; Zeng Q.; Nitta H.; Hirano S.; Effects of PAMAM dendrimers in the mouse brain after a single intranasal instillation. Toxicol Lett 2014,228(3),207-215","journal-title":"Toxicol Lett"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1208\/s12249-014-0189-5","volume":"15","author":"Baltzley S.","year":"2014","unstructured":"Baltzley S.; Mohammad A.; Malkawi A.H.; Al-Ghananeem A.M.; Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles. AAPS PharmSciTech 2014,15(6),1598-1602","journal-title":"AAPS PharmSciTech"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ijbiomac.2014.03.022","volume":"67","author":"Bhavna M.S.","year":"2014","unstructured":"Bhavna M.S.; Ali M.; Ali R.; Bhatnagar A.; Baboota S.; Ali J.; Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation. Int J Biol Macromol 2014,67,418-425","journal-title":"Int J Biol Macromol"},{"key":"ref=227","author":"Maurya P.","unstructured":"Maurya P.; Mittal A.; Sharma K.; Alam S.;  Fabrication of\nacetazolamide loaded nasal nanosuspension: an in vitro and\nex vivo characterization. Analele Univ. \u201cDun\u0103rea Jos\u201d\nGala\u0163i., 2013, 17(1), 93-105."},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1016\/j.actbio.2011.07.025","volume":"7","author":"Seju U.","year":"2011","unstructured":"Seju U.; Kumar A.; Sawant K.K.; Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater 2011,7(12),4169-4176","journal-title":"Acta Biomater"},{"key":"ref=229","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/156010","volume":"2014","author":"Sharma D.","year":"2014","unstructured":"Sharma D.; Maheshwari D.; Philip G.; Rana R.; Bhatia S.; Singh M.; Gabrani R.; Sharma S.K.; Ali J.; Sharma R.K.; Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using box-behnken design: in vitro and in vivo evaluation. BioMed Res Int 2014,2014","journal-title":"BioMed Res Int"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2147\/IJN.S120939","volume":"11","author":"Bi C.","year":"2016","unstructured":"Bi C.; Wang A.; Chu Y.; Liu S.; Mu H.; Liu W.; Wu Z.; Sun K.; Li Y.; Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson\u2019s disease treatment. Int J Nanomedicine 2016,11,6547-6559","journal-title":"Int J Nanomedicine"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bdd.621","volume":"29","author":"Cheng Q.","year":"2008","unstructured":"Cheng Q.; Feng J.; Chen J.; Zhu X.; Li F.; Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: a microdialysis study. Biopharm Drug Dispos 2008,29(8),431-439","journal-title":"Biopharm Drug Dispos"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/10611860903483396","volume":"18","author":"Al-Ghananeem A.M.","year":"2010","unstructured":"Al-Ghananeem A.M.; Saeed H.; Florence R.; Yokel R.A.; Malkawi A.H.; Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target 2010,18(5),381-388","journal-title":"J Drug Target"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10717544.2014.948643","volume":"23","author":"Alex A.T.","year":"2014","unstructured":"Alex A.T.; Joseph A.; Shavi G.; Rao J.V.; Udupa N.; Development and Evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery. Drug Deliv 2014,23(7),1-10","journal-title":"Drug Deliv"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1002\/jps.24557","volume":"104","author":"Elnaggar Y.S.R.","year":"2015","unstructured":"Elnaggar Y.S.R.; Etman S.M.; Abdelmonsif D.A.; Abdallah O.Y.; Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer\u2019s disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 2015,104(10),3544-3556","journal-title":"J Pharm Sci"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","volume":"461","author":"Zhang C.","year":"2014","unstructured":"Zhang C.; Chen J.; Feng C.; Shao X.; Liu Q.; Zhang Q.; Pang Z.; Jiang X.; Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer\u2019s disease. Int J Pharm 2014,461(1-2),192-202","journal-title":"Int J Pharm"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3109\/10717544.2014.907372","volume":"23","author":"Mittal D.","year":"2016","unstructured":"Mittal D.; Md S.; Hasan Q.; Fazil M.; Ali A.; Baboota S.; Ali J.; Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv 2016,23(1),130-139","journal-title":"Drug Deliv"},{"key":"ref=237","unstructured":"EMA, 2014. Human Regulatory, Quality By Design, Guidance\nDocuments. http:\/\/ Available at: ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/document_listing\/document_listing_000162.jsp\">www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/document_listing\/document_listing_000162.jsp"},{"key":"ref=238","unstructured":"FDA Guidance for Industry: Nasal Spray and Inhalation\nSolution, Suspension, and Spray Drug Products. Available\nat:  ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.gmp-compliance.org\/guidemgr\/files\/4234FNL.PDF\">http:\/\/www.gmp-compliance.org\/guidemgr\/files\/4234FNL.PDF [Accessed:\nJul 24, 2017]."},{"key":"ref=239","unstructured":"FDA. Guidance for Industry Metered Dose Inhaler (MDI)\nand Dry Powder Inhaler (DPI) Drug Products. 1998, No.\nOctober, 1-65. Available at:  https:\/\/elsmar.com\/elsmarqualityforum\/attachments\/mdi-dpis-fda-guideline-pdf.14553\/ [Accessed: Jul 24, 2017]."},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"S3412","DOI":"10.1016\/j.arabjc.2014.01.025","volume":"10","author":"Sangshetti J.N.","year":"2014","unstructured":"Sangshetti J.N.; Deshpande M.; Zaheer Z.; Shinde D.B.; Arote R.; Quality by design approach: regulatory need. Arab J Chem 2014,10(Suppl. 2),S3412-S3425","journal-title":"Arab J Chem"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ijpharm.2015.06.018","volume":"491","author":"Pallagi E.","year":"2015","unstructured":"Pallagi E.; Ambrus R.; Szab\u00f3-R\u00e9v\u00e9sz P.; Cs\u00f3ka I.; Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation. Int J Pharm 2015,491(1-2),384-392","journal-title":"Int J Pharm"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejps.2015.07.002","volume":"78","author":"Shah B.","year":"2015","unstructured":"Shah B.; Khunt D.; Bhatt H.; Misra M.; Padh H.; Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci 2015,78,54-66","journal-title":"Eur J Pharm Sci"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10837450.2016.1236130","volume":"23","author":"Chudiwal S.S.","year":"2016","unstructured":"Chudiwal S.S.; Dehghan M.H.G.; Quality by Design (QbD) Approach for design and development of drug-device combination products: a case study on flunisolide nasal spray. Pharm Dev Technol 2016,23(10),1-10","journal-title":"Pharm Dev Technol"},{"key":"ref=244","first-page":"861","volume":"7","author":"Sinsuebpol C.","year":"2013","unstructured":"Sinsuebpol C.; Chatchawalsaisin J.; Kulvanich P.; Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel Ther 2013,7,861-873","journal-title":"Drug Des Devel Ther"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","volume":"3","author":"Djupesland P.G.","year":"2013","unstructured":"Djupesland P.G.; Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res 2013,3(1),42-62","journal-title":"Drug Deliv Transl Res"},{"key":"ref=246","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/pharmaceutics6020195","volume":"6","author":"Trows S.","year":"2014","unstructured":"Trows S.; Wuchner K.; Spycher R.; Steckel H.; Analytical challenges and regulatory requirements for nasal drug products in Europe and the U.S. Pharmaceutics 2014,6(2),195-219","journal-title":"Pharmaceutics"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2500\/ar.2016.7.0185","volume":"7","author":"Yanez A.","year":"2016","unstructured":"Yanez A.; Dimitroff A.; Bremner P.; Rhee C-S.; Luscombe G.; Prillaman B.A.; Johnson N.; A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol (Providence) 2016,7(4),183-192","journal-title":"Allergy Rhinol (Providence)"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2045-7022-2-9","volume":"2","author":"Hellings P.W.","year":"2012","unstructured":"Hellings P.W.; Dobbels F.; Denhaerynck K.; Piessens M.; Ceuppens J.L.; De Geest S.; Explorative study on patient\u2019s perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis. Clin Transl Allergy 2012,2(1),9","journal-title":"Clin Transl Allergy"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clinthera.2007.01.014","volume":"29","author":"Chao J.","year":"2007","unstructured":"Chao J.; Nau D.P.; Aikens J.E.; Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. Clin Ther 2007,29(1),177-180","journal-title":"Clin Ther"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/WOX.0b013e3181865f99","volume":"1","author":"Fromer L.M.","year":"2008","unstructured":"Fromer L.M.; Ortiz G.R.; Dowdee A.M.; Assessment of patient attitudes about mometasone furoate nasal spray: the ease-of-use patient survey. World Allergy Organ J 2008,1(9),156-159","journal-title":"World Allergy Organ J"},{"key":"ref=251","unstructured":"U.S. Food and Drug Administration. Guidance for Industry.\nIntegration of Dose-Counting Mechanisms into MDI Drug\nProducts. 2003. March. Available at:  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/integration-dose-counting-mechanisms-mdi-drug-products [Accessed: Jul 24, 2017]"},{"key":"ref=252","unstructured":"European medicines agency. Outcome Report on Pilot to\nInvolve Patients in Benefit \/ Risk Discussions at CHMP\nMeetings. 2017, 44 (March). Available at:  https:\/\/www.ema.europa.eu\/en\/documents\/report\/outcome-report-pilot-involve-patients-benefit\/risk-discussions-chmp-meetings_en.pdf [Accessed: Jul 24, 2017]"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T11:26:51Z","timestamp":1579692411000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174478\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":252,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2019,12,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666190827151741","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}